FDA End of Phase 2 meeting for AD04 set for July 25, 2025. AD04 targets heavy drinking AUD patients with < 8 drinks/day. Want to trade this news? Get access to the 34-0 income strategy that loves ...
Primary Endpoint met: Statistically significant reduction in blood-fat levels after eating (-51.9%) Multiple secondary endpoints met: Including statistically significant reduction in weight regain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback